In the rush to control health-care costs, don't chill biotech drug innovation
It's not the stuff of a town hall shouting match, but one of the most far-reaching elements of the national debate over health care is the question of how long to protect breakthrough drugs produced by biotechnology from copycat generics. One side argues that five years...